Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02 2024 - 4:30PM
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq:
OLMA), a clinical-stage biopharmaceutical company focused on the
discovery, development, and commercialization of targeted therapies
for women’s cancers, today announced that the Company granted stock
options to four new employees to purchase an aggregate of 33,600
shares of the Company's common stock, effective as of February 1,
2024. These awards were approved by the Compensation Committee of
Olema’s Board of Directors and granted under the Company's 2022
Inducement Plan, with a grant date of February 1, 2024, as an
inducement material to the new employees entering into employment
with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting
on the first anniversary of the vesting commencement date for such
employee and the remainder vesting in 36 equal monthly installments
over the following three years, subject to the employee being
continuously employed by Olema as of such vesting dates. The stock
options have a 10-year term and an exercise price of $15.25 per
share, equal to the last reported sale price of the Company's
common stock as reported by Nasdaq on February 1, 2024. The stock
options are subject to the terms of the Olema Pharmaceuticals,
Inc., 2022 Inducement Plan.
Olema is providing this information in accordance with Nasdaq
Listing Rule 5635(c)(4).
About Olema OncologyOlema Oncology is a
biopharmaceutical company committed to transforming the standard of
care and improving outcomes for women living with cancer. Olema is
advancing a pipeline of novel therapies by leveraging our deep
understanding of endocrine-driven cancers, nuclear receptors, and
mechanisms of acquired resistance. In addition to our lead product
candidate, palazestrant (OP-1250), a proprietary, orally-available
complete estrogen receptor (ER) antagonist (CERAN) and a selective
ER degrader (SERD), Olema is developing a potent KAT6 inhibitor
(OP-3136). Olema is headquartered in San Francisco and has
operations in Cambridge, Massachusetts. For more information,
please visit us at www.olema.com.
Contact:Geoffrey Mogilner, Vice President, Investor Relations
and Communicationsir@olema.com
Olema Pharmaceuticals (NASDAQ:OLMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Olema Pharmaceuticals (NASDAQ:OLMA)
Historical Stock Chart
From Apr 2023 to Apr 2024